On July 4, President Trump signed H.R. 1, often referred to as the One Big Beautiful Bill Act, into law.

Key insights from the discussion related to supporting patient needs in MS, advancing understanding of MS, emerging treatments in MS, using real-world evidence in MS coverage decision-making, and addressing continued challenges in MS. Suggested payer best practices in MS also emerged from the discussion.

This toolkit makes it easy to share your Unscripted—The AMCP Podcast episode, highlight your insights, and amplify your voice across your network.

On July 4, President Donald Trump signed H.R. 1, the One Big Beautiful Bill Act, into law.

Medicare Part D sponsors must have concurrent drug utilization review (DUR) systems, policies, and procedures designed to ensure that a review of the prescribed drug therapy is performed before each prescription is dispensed to an enrollee in a sponsor’s Part D plan, typically at the POS or point of distribution as described in 42 CFR § 423.153(c)(2).

H.R. 1 will result in less preventive care and more preventable emergency room visits, increasing costs for everyone across the health care system and threatening hospitals with closure, which will further reduce access to critical care for American patients.

Each fall, thousands of managed care professionals gather for AMCP Nexus, a dynamic meeting you'll connect with the people, ideas, and innovations shaping the future of pharmacy and health care. Nexus 2025 is shaping up to be our most engaging and insightful gathering yet with new features, big names, and an even greater focus on connection, wellness, and professional growth.

Last week, AMCP convened a diverse group of stakeholders for its Precision Medicine Partnership Forum to examine solutions that improve access, consistency, and quality in precision oncology.

Read the Journal of Managed Care + Specialty Pharmacy (JMCP) June 2025 Issue